Replies to post #304172 on Avid Bioservices Inc (CDMO)

[JamesGMS]

KT, just a comment related to your post excerpted in relevant part below:

Oops, the faction on Item T was for that Phase 2 study where the dose switching left PPHM retail shareholders "at the altar" after the run up to over $5 1/2 pps, pre split.

The Phase 3 trial halt was on its own path. There were at least three unusual trial results related events that left expectations for PPHM successful commercialization with a set back, by my recollection:

1. the unusual control group performance that showed the placebo group outperforming previous trial control groups by a large margin. . . . . . . . .

The Phase III result was particularly difficult as Garnick et al were highly confident of an approval - most likely after the second look, and, as reiterated to me once again by a close associate of Dr. Garnick just last week, Bavi did indeed perform exactly as expected - actually better than Opdivo in a very similar trial - which really made our result that much more difficult to understand. Dr. Garnick did his job - Bavi should have been approved last year.

Enjoy your evening.

James